


Evaluation of implementation of Regional Flagship Areas in the WHO South-East Asia Region 2014–2018



Evaluation of Implementation of Regional Flagship Areas in the WHO South-East Asia Region 2014–2018



World Health
Organization
REGIONAL OFFICE FOR
South-East Asia

This report has been prepared by IQVIA Consulting and Information Services India Private Limited, New Delhi. IQVIA is a global leader in providing health-care advisories, consultation and research, performance management, technical assistance, technology and data analytics services, to both the public and private sector. The company was founded in 1954 (presence in India since 2000), and today is a 'Fortune 500' company with revenue of US\$ 10 billion, with over 50 000 employees operating in more than 100 countries around the world, with thousands of proprietary methodologies, including patented systems for analytics, data encryption and forecasting. IQVIA is publicly listed on the New York Stock Exchange serving more than 5 000 health-care clients globally. More about IQVIA may be found on its website www.iqvia.com.

Evaluators

Mr Nilesh Maheshwari

Mr Kaartik Chauhan

Ms Kavya Sharma

Ms Manjari Sharma

Dr Jyotiee Mehraa

Ms Iti Kaushik

Ms Vidhi Gupta

Dr Garima Kalra

Dr Shiny Sohal

Ms Ria Golecha

Ms Rimjhim Mishra

IQVIA Consulting and Information Services India Private Limited

New Delhi, India

www.iqvia.com

Disclaimer: The analysis, opinions, conclusions and recommendations in this report are those of the independent evaluation team and do not necessarily reflect the views and procedures of the World Health Organization.

Evaluation of Implementation of Regional Flagship Areas in the WHO South-East Asia Region 2014–2018

ISBN: 978-92-9022-806-6

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO); <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>.

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization..

Suggested citation. Evaluation of Implementation of Regional Flagship Areas in the WHO South-East Asia Region 2014–2018. New Delhi: World Health Organization, Regional Office for South-East Asia; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in India

Contents

<i>Acknowledgements</i>	v
<i>List of abbreviations</i>	vi
<i>List of figures</i>	ix
<i>List of tables</i>	xi
<i>Executive summary</i>	xiii
Section 1: Introduction	1
Section 2: Evaluation objectives and methodology	4
2.1 Purpose and objectives of the evaluation	4
2.2 Evaluation scope	4
2.3 Evaluation questions	5
2.4 Evaluation framework	5
2.5 Evaluation design	6
2.6 Theory of change	9
Section 3: Evaluation Findings	11
3.1 Measles elimination and rubella control by 2020	13
3.2 Prevention of NCDs through multisectoral policies and plans with focus on best buys	25
3.3 The unfinished MDG agenda: ending preventable maternal, newborn and child deaths with a focus on neonatal deaths	41
3.4 Universal health coverage with focus on human resources for health and essential medicines	55
3.5 Building national capacity for preventing and combating antimicrobial resistance	70
3.6 Scaling up capacity development in emergency risk management in countries	82

3.7	Finishing the task of eliminating diseases on the verge of elimination (kala-azar, leprosy, lymphatic filariasis and yaws)	95
3.8	Accelerating efforts to end TB by 2030	106
Section 4: Enabling factors and challenges		118
4.1	Enabling factors	118
4.2	Challenges	119
Section 5: Conclusion		121
Section 6: The way forward		126
Section 7: Recommendations		129
7.1	Recommendations for the WHO Secretariat	129
7.2	Recommendations for ministries of health/Member States	

Annexes

I.	Evaluation framework	132
II.	Secondary review methodology	133
III.	Quality assurance measures	134
IV.	Rigor	135
V.	Evaluation management group	136
VI.	Stakeholders interviewed	137
VII.	Discussion guides	152
VIII.	List of references	156

Acknowledgements

We are thankful to Dr Poonam Khetrpal Singh, Regional Director, World Health Organization (WHO) South-East Asia Region, for commissioning this evaluation.

The evaluation team would like to thank all the participants in this evaluation for their contributions and their availability, which helped us in the timely execution of the study. We appreciate the generosity of all the representatives from the ministries of health in all 11 South-East Asia (SEA) Region countries for their esteemed thoughts and feedback about the Regional Flagship Areas. We would also like to thank all the representatives from technical and donor partners who gave their time generously for this evaluation.

We extend our gratitude to Director Programme Management (DPM), programme directors, and regional advisers at WHO-South-East Asia Regional Office (SEARO) for making the time for interviews and discussions, and giving us their valuable opinions and perspectives. Their insights and perspectives on WHO's role and contributions to the WHO-SEARO's eight Regional Flagship Areas were invaluable.

We would like to express our special gratitude to the country WHO representatives of all 11 SEA Region countries and WHO country office staff for their valuable insights. Their contribution and willingness to facilitate discussions with different groups of stakeholders at various ministries of health and technical and donor partners was critical to ensure a holistic view of WHO's work.

This evaluation would not have been possible without the contributions of some extraordinary people. We would like to express our sincere gratitude to the members of the Evaluation Management Group (EMG) – Dr Elil Renganathan (Co-chair and DG Representative for Evaluation and Organisational Learning, WHO-HQ), Dr Pem Namgyal (Co-chair and Director, Programme Management, WHO-SEARO), Dr Rajesh Pandav (WHO Representative to Timor-Leste), Mr Robert J McCouch (Chief Evaluation Officer, WHO-HQ), Dr Tasnim Azim (Regional Adviser, Research and Policy Coordination, Department of Communicable Diseases, WHO-SEARO) and Dr Rakesh Mani Rastogi (Technical Officer, Health Situation and Trend Assessment, Department of Health Systems and Life-Course, WHO-SEARO) for their endless patience and valuable insights into the evaluation.

We are immeasurably indebted to the core members of the Programme Planning and Coordination (PPC) team – Mr Rony Maza (Coordinator, Programme Planning, Monitoring and Evaluation, WHO-SEARO), Dr Anuruddhe Thushara Ranasinghe (Programme Management Officer, WHO-SEARO), Dr Rahul Srivastava (Technical Officer, Regional Director's Office, WHO-SEARO) and Dr Anton Fric (Consultant, WHO-SEARO) for their constant support, guidance and inputs throughout the evaluation.

This evaluation would not have been feasible without the respondents' reflection and their endless patience and acumen for reinforcing the team's understanding..

List of abbreviations

AEFI	Adverse Event following Immunization
AMR	Antimicrobial Resistance
APSED	Asia Pacific Strategy for Emerging Diseases
B SMART	Bhutan's Structured and Mentoring Approach to Research Training
BHTF	Bhutan Health Trust Fund
CRS	Congenital Rubella Syndrome
DIPECHO	Disaster Preparedness Programme of the European Commission Humanitarian Office
DPM	Director Programme Management
EMG	Evaluation Management Group
EML	Essential Medicine List
EmOC	Emergency Obstetric care
EMT	Emergency Medical Team
EPI	Extended Programmes of Immunization
EQA	External Quality Assurance
FAO	Food and Agriculture Organization of the United Nations
FETP	Field Epidemiology Training Programme
GAP	Global Action Plan
GAPPA	Global Action Plan on Physical Activity
GATS	Global Adult Tobacco Survey
GLASS	Global Antimicrobial Resistance Surveillance System
GMRLN	Global Measles and Rubella Laboratory Network

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report?>